Product image of Gluscan (Fludeoxyglucose (18f)) supplied by GNH India

Gluscan

Active Ingredient:
Fludeoxyglucose (18f)
Origin:
EU

Gluscan (Fludeoxyglucose (18f))

Gluscan is a radiopharmaceutical product containing the active ingredient fludeoxyglucose (18F) supplied as an injectable solution for intravenous administration. It is marketed in the European Union and is prescribed for diagnostic imaging using positron emission tomography (PET). The compound acts as a glucose analog, enabling visualization of metabolic activity in various tissues, which supports clinical assessment in oncology, cardiology, and neurology and research applications worldwide.

Manufacturer / TM Owner

Advanced Accelerator Applications Molecular Imaging France S.A.S.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Gluscan is employed primarily as a tracer in PET scans to assess glucose metabolism in target organs.

  • Oncology: detection, staging, and monitoring of malignant tumors.
  • Cardiology: evaluation of myocardial viability and perfusion.
  • Neurology: assessment of cerebral glucose utilization in epilepsy and dementia.
  • Research: quantification of metabolic activity in clinical trials.
  • Whole-body imaging: identification of metastatic disease.

Side Effects

Adverse reactions to Gluscan are generally mild, but rare serious events have been reported.

Common

  • Transient flushing or warmth at the injection site.
  • Mild nausea or vomiting.
  • Short-term headache.
  • Temporary metallic taste.

Serious

  • Severe allergic reaction (anaphylaxis) with rash, bronchospasm, or hypotension.
  • Significant radiation-induced tissue injury in high-dose exposures.
  • Persistent vomiting or seizures related to metabolic disturbances.

Precautions & Warnings

Use of Gluscan requires careful consideration of patient factors and procedural conditions to ensure safety.

  • Verify pregnancy status; avoid use unless benefit outweighs potential fetal radiation risk.
  • Assess renal function, as impaired clearance may increase radiation exposure.
  • Ensure fasting for at least 4–6 hours before injection to reduce background glucose uptake.
  • Review recent administration of other radiopharmaceuticals to avoid cumulative dose.
  • Monitor for signs of hypersensitivity during and after injection.
  • Adjust dose in pediatric patients according to body weight and clinical protocol.

Avoid Interactions

Gluscan may interact with other substances that affect glucose metabolism or radiation exposure.

Avoid

  • Concurrent use of high-dose iodinated contrast agents immediately before PET, which can alter biodistribution.
  • Administration of other radiopharmaceuticals within 24 hours, leading to overlapping radiation fields.

Use with caution

  • Antidiabetic medications (insulin, oral hypoglycemics) that modify blood glucose levels; glucose should be controlled before imaging.
  • Chemotherapeutic agents that cause bone‑marrow suppression, potentially affecting tracer uptake.
  • Corticosteroids, which may influence metabolic activity and PET interpretation.

Frequently Asked Questions

Gluscan contains fludeoxyglucose (18F), a glucose analog that is taken up by metabolically active cells and phosphorylated, allowing PET scanners to visualize tissue glucose metabolism.

Gluscan is used in oncology for tumor detection, in cardiology to assess myocardial viability, and in neurology to evaluate cerebral glucose metabolism.

Patients are typically advised to fast for 4–6 hours prior to injection to minimize background glucose levels and to avoid recent high-dose contrast agents.

Gluscan is generally avoided during pregnancy because of radiation exposure; it should only be used when the diagnostic benefit justifies the potential risk.

Common side effects include transient flushing or warmth at the injection site, mild nausea, short‑term headache, and a temporary metallic taste.

Yes, although rare, Gluscan can trigger severe allergic reactions such as anaphylaxis, which require immediate medical attention.

Diabetic patients should discuss glucose control with their physician; antidiabetic medications may need adjustment to achieve appropriate blood glucose levels for accurate imaging.

The radioactive fluorine‑18 isotope has a half‑life of approximately 110 minutes, and most of the activity is eliminated within a few hours after injection.

Yes, other radiopharmaceuticals should generally be avoided for at least 24 hours to prevent overlapping radiation exposure.

Standard cardiac PET protocols include resting and stress imaging, with glucose levels controlled and acquisition timed to the peak uptake of the tracer.

Gluscan may be used in children, but dosing is typically weight‑based and performed under strict pediatric imaging guidelines.

Severe nausea should be reported to the imaging team; supportive care and monitoring are provided, and the event is documented for safety records.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Fludeoxyglucose (18f)

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT